Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TASUC-Neo: Degarelix + Gemcitabine/Cisplatin in Muscle-Invasive Urothelial Cell Carcinoma
NCT05839119Phase 1Terminated
- Sponsor
- Brown University
- Start
- Oct 2023
- Primary completion
- Jul 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of degarelix in urothelial carcinoma (UC), sponsored by Brown University. Primary endpoint: Pathologic Complete Response Rate. Started Oct 2023; status: terminated.
02
Drugs
degarelix
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05839119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05839119.